Key Patent Granted for ORAVEXX by United States Patent and Trademark Office
Orcosa
  • Technology
    Technology
    • RITe™ Platform

      Our breakthrough, proprietary technology platform engineered to enhance drug absorption

    • Capabilities

      End-to-end, in-house control of formulation, development, and manufacturing capabilities

  • Research
    Research
    • ORAVEXX™ Research + Development

      Our proprietary cannabinoid composition for the management of pain and inflammation

    • Research Partners

      Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials

    • About Cannabidiol

      Learn more about cannabidiol from the medical community and regulators

  • Company
    Company
    • About Us

      We are modernizing the way medicines are taken

    • Our Team

      Experts in drug development and delivery, manufacturing, and commercialization

  • News
    News
    • In the News

      Recent media coverage regarding Orcosa

    • Press Releases and Blog Posts

      Company news and announcements

  • Careers
    Careers
Contact

Press Releases
and Blog Posts

Jun 14, 2023
Orcosa Announces Key Patent Granted by USPTO for ORAVEXX™ in Acute Pain
Sep 02, 2022
Orcosa Announces Positive Results from Phase 1/2 clinical trial utilizing ORAVEXX™ to be Presented at the European Society for Surgery of the Shoulder and Elbow, 30th SECEC-ESSSE Congress in Dublin
Aug 01, 2022
Orcosa Congratulates Michael J. Alaia, M.D., and Researchers at NYU Langone and Baptist Health on Publication of Landmark Results from Phase 1/2 Clinical Trial Utilizing ORAVEXX™ in The American Journal of Sports Medicine 
Jul 22, 2022
Statement on Enrollment of First Patient in NYU Langone Health’s Phase 2 Clinical Trial Utilizing ORAVAEXX™
« Previous 1 2 3 4 5 Next »
  • Technology
  • Research
  • Company
  • Careers
Orcosa
© 2024 Orcosa. All rights reserved.
  • Privacy Policy
  • Accessibility Statement